The Horizon 2020 project DeteCTCs initiates clinical study for development of next generation CTC-based cancer diagnostics
Stockholm, Sweden. May 24, 2022. iCellate Medical AB, in association with the University Medical Center Schleswig-Holstein and QIAGEN, Inc. are proud to announce that the clinical study portion of their joint project DeteCTCs, subsidized by the EU Horizon 2020 programme, has included its first study subject.We are excited to announce the enrollment of the first subject into the clinical study portion of the DeteCTCs project, to accelerate the continued development of iCellate’s next-generation CellMate[®] in vitro diagnostic platform. Over two years, this study will enroll approximately 260